Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:23 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 10,492 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Not applicable Interventional

Improving Control of Alignment in Intermittent Exotropia

NCT04199871
View directory record Official record
Conditions
Intermittent Exotropia
Interventions
dichoptic 3D movies
Other
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
3 Years to 12 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

FDG-PET Imaging in Complicated Diabetic Foot

NCT00194298
View directory record Official record
Conditions
Diabetic Foot Disease
Interventions
FDG-PET Imaging
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

Clinical Assessment of Low Calcium In traUMa (CALCIUM)

NCT05885256
View directory record Official record
Conditions
Hypocalcemia
Interventions
Amending current standard trauma order set
Diagnostic Test
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI

NCT05525845
View directory record Official record
Conditions
Healthy
Interventions
Functional Magnetic Resonance Imaging (pCASL-MRI), Intragastric Balloon, Elemental Meal, Hedonic Meal
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Not applicable Interventional

Testing a Brief Reassurance Message Before a Musculoskeletal Clinic Visit

NCT07330492
View directory record Official record
Conditions
Any Non-traumatic Musculoskeletal Condition
Interventions
Nudge intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

Evaluating the Effects of Genetic Testing on Patients' Stress Levels

NCT02783664
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaires to Evaluate Anxiety Related to Genetic Testing
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Not applicable Interventional

Efficacy of a Dental Implant System for Immediate Restoration

NCT06651502
View directory record Official record
Conditions
Missing Teeth
Interventions
dental implant placement and immediate provisionalization
Device
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
20 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

NCT05203939
View directory record Official record
Conditions
Retinitis Pigmentosa, Leber Congenital Amaurosis
Interventions
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
Drug
Lead sponsor
Ocugen
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 2 Interventional Results available

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

NCT03722407
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892
View directory record Official record
Conditions
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

NCT06941844
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

NCT04042831
View directory record Official record
Conditions
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

NCT05394337
View directory record Official record
Conditions
Metastatic Malignancy
Interventions
Atezolizumab, Tiragolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

NCT05134857
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 2 Interventional

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
View directory record Official record
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Not applicable Interventional

Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis

NCT04518657
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Behavioral Intervention for Physical Activity in MS (BIPAMS), Wellness for MS (WellMS)
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 2 Interventional

Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

NCT04175301
View directory record Official record
Conditions
Malignant Glioma
Interventions
Hydrogen, Placebo oral tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201
View directory record Official record
Conditions
Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, Bay94-9027)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

NCT03442101
View directory record Official record
Conditions
Psychosis
Interventions
Patients with psychosis will be treated with known antipsychotic medication
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related

NCT06765681
View directory record Official record
Conditions
Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
Interventions
Diagnosis of both VTE and sepsis
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
eneboparatide, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Not applicable Interventional

Virtually Supervised Exercise for Kidney Transplant Candidates

NCT05355545
View directory record Official record
Conditions
Physical Disability
Interventions
Virtually supervised exercise, Health education
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 3 Interventional Results available

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01886872
View directory record Official record
Conditions
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
917
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting Phase 1 Interventional

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 3, 2026, 4:23 PM EST